FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00606528

Recruitment Status : Completed

First Posted : February 4, 2008

Last Update Posted : July 25, 2013

Sponsor:

Information provided by (Responsible Party):

University Health Network, Toronto

Study Description

Brief Summary:

The main objective of this study is to assess whether a recently-developed bioassay for the protein FGL2 can be used to predict the progression and/or response to treatment of Hepatitis C Virus disease in patients with chronic HCV infection. The hypothesis is that increased levels of FGL2 and increased numbers of T regulatory cells are associated with a failure to respond to treatment.

Condition or disease	Intervention/treatment
Chronic Hepatitis C Virus Infection	Other: No intervention

Detailed Description:

The current therapy for chronic Hepatitis C Virus infection leads to a sustained viral response in only 50% of treated patients. Evidence suggests that a poor response to treatment may be the result of a dysfunction of immunoregulatory mediators including T regulatory cells (Tregs) which secrete FGL2. The aim of this study is to test whether serum FGL2 levels can serve as a biomarker for clinical progress and treatment response in patients undergoing anti-viral therapy for chronic HCV infection.

This study will measure the blood Treg and FGL2 levels of patients with chronic Hepatitis C as they undergo antiviral therapy and will compare those levels to their pre-treatment and post-treatment levels. Treg and FGL2 expression levels will also be measured in patients' liver biopsy tissue when available.

Additionally, this study will examine the main form(s)of Fc Receptor expressed in these patients. The Fc receptor is the hypothesized binding partner of FGL2, and the form expressed in a given patient may determine the downstream effects of FGL2's binding. These data along with clinical, biochemical and virological data will be used to determine whether there is a correlation between FGL2 levels and disease outcome and/or treatment response.

The study will also recruit a group of normal healthy volunteers to give blood samples on two occasions so that the baseline range of FGL2 levels in healthy individuals can be established for comparison.

Study Design

Layout table for study information

Study Type :	Observational
Actual Enrollment :	54 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy
Study Start Date :	February 2008
Actual Primary Completion Date :	July 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hepatitis Hepatitis A Hepatitis C

U.S. FDA Resources

Groups and Cohorts

Group/Cohort	Intervention/treatment
Group A patients with chronic Hepatitis C Virus infection who have not previously received antiviral therapy	Other: No intervention None. This is an observational study.
Group B Healthy volunteers willing to donate blood on 2 separate occasions

Outcome Measures

Primary Outcome Measures :

correlation between blood FGL2 levels and response to antiviral therapy [ Time Frame: 6 months after the end of treatment ]

Secondary Outcome Measures :

correlation between FGL2 levels and Treg percentage in blood and liver cells [ Time Frame: all time points ]

Biospecimen Retention: Samples With DNA

Whole Blood Plasma Liver tissue from biopsy

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Chronic HCV treatment-naive patients who are willing to begin antiviral therapy

Criteria

HCV patient population

Inclusion Criteria:

able to give written consent
18-70 yrs of age, both genders
willing to use adequate contraception
diagnosis of chronic HCV infection (of any genotype) based on 2 positive serology tests
availability of pre- and post-treatment viral load data
naive to antiviral treatment
availability of pre-treatment liver biopsy

Exclusion Criteria:

less than 18 yrs, greater than 70 yrs of age
pregnancy
HBV, HDV, or HIV co-infection
any history of active alcohol or drug abuse

Volunteer Population (Control)

Inclusion Criteria:

able and willing to provide written informed consent
willing to provide a brief review of medical history
18-70 yrs of age, of either gender

Exclusion Criteria:

less than 18, greater than 70 yrs of age
any history of liver, renal, lung, hematological or coronary artery disease
any history of active alcohol or drug abuse
any previous diagnosis of HBV, HCV, HDV or HIV

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00606528

Locations

Layout table for location information

Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2C4

Sponsors and Collaborators

University Health Network, Toronto

Investigators

Layout table for investigator information

Principal Investigator:	Gary Levy, MD	University Health Network, Toronto

More Information

Publications:

Shalev I, Liu H, Koscik C, Bartczak A, Javadi M, Wong KM, Maknojia A, He W, Liu MF, Diao J, Winter E, Manuel J, McCarthy D, Cattral M, Gommerman J, Clark DA, Phillips MJ, Gorczynski RR, Zhang L, Downey G, Grant D, Cybulsky MI, Levy G. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. J Immunol. 2008 Jan 1;180(1):249-60.

Liu H, Zhang L, Cybulsky M, Gorczynski R, Crookshank J, Manuel J, Grant D, Levy G. Identification of the receptor for FGL2 and implications for susceptibility to mouse hepatitis virus (MHV-3)-induced fulminant hepatitis. Adv Exp Med Biol. 2006;581:421-5.

Chan CW, Kay LS, Khadaroo RG, Chan MW, Lakatoo S, Young KJ, Zhang L, Gorczynski RM, Cattral M, Rotstein O, Levy GA. Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. J Immunol. 2003 Apr 15;170(8):4036-44.

Layout table for additonal information

Responsible Party:	University Health Network, Toronto
ClinicalTrials.gov Identifier:	NCT00606528
Other Study ID Numbers:	07-0841-T
First Posted:	February 4, 2008 Key Record Dates
Last Update Posted:	July 25, 2013
Last Verified:	July 2013

Keywords provided by University Health Network, Toronto:


Antiviral therapy

Additional relevant MeSH terms:

Layout table for MeSH terms

Infection Communicable Diseases Hepatitis A Virus Diseases Hepatitis C Hepatitis C, Chronic Hepatitis Liver Diseases	Digestive System Diseases Hepatitis, Viral, Human Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections Hepatitis, Chronic

To Top